Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.

@article{Arin2005AntiBCI,
  title={Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.},
  author={Meral Julia Arin and Nicolas Hunzelmann},
  journal={European journal of dermatology : EJD},
  year={2005},
  volume={15 4},
  pages={224-30}
}
Rituximab is a monoclonal antibody directed against the CD20 surface antigen present on B lymphocytes. Following its application, B cells are rapidly and specifically depleted. Rituximab has been approved for the treatment of relapsed and therapy-refractory non-Hodgkin lymphoma and has been incorporated into numerous chemotherapy regimes with promising results. Eradication of auto-reactive B cell clones is the rationale for its application in a variety of autoimmune disorders including the… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…